EUVIMEDEUVIMED entdecken
Crossref

Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor

Yu Cai iD, Jianlin He, Zhipeng Wu, Weigang He, Xiaoming Dai, Yan Xu, Min Cheng, Na Yang, Yongxin Ren, Guanglin Wang, Jian Wang, Yang Sai und 4 weitere

The Journal of Pharmacology and Experimental Therapeutics · 2024-01 · 388 (1) · 156-170

DOI: 10.1124/jpet.123.001752 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2024-01. Verfasst von Yu Cai und 15 weiteren Autor:innen. Beteiligte Einrichtung: HUTCHMED Limited, Shanghai, China yuc@hutch-med.com. Hauptthemen laut MEDLINE: Autoimmune Diseases, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune DiseasesNeoplasmsRatsMiceHumansAnimalsProtein-Tyrosine KinasesSyk KinaseSignal TransductionProtein Kinase Inhibitors

Substanzen

Protein-Tyrosine KinasesSyk KinaseProtein Kinase Inhibitors

Autor:innen und Institutionen

  • HUTCHMED Limited, Shanghai, China yuc@hutch-med.com.
  • HUTCHMED Limited, Shanghai, China.

ORCID-Profile: Yu Cai

Zitieren

APA

Cai, Y., He, J., Wu, Z., He, W., Dai, X., Xu, Y., Cheng, M., Yang, N., Ren, Y., Wang, G., Wang, J., Sai, Y., Jia, H., Dai, G., Li, X., & Su, W. (2024). Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor. The Journal of Pharmacology and Experimental Therapeutics, 388(1), 156-170. https://doi.org/10.1124/jpet.123.001752

Vancouver

Cai Y, He J, Wu Z, He W, Dai X, Xu Y, et al. Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor. The Journal of Pharmacology and Experimental Therapeutics. 2024;388(1):156-170. doi:10.1124/jpet.123.001752

BibTeX
@article{Cai2024,
  author = {Cai, Yu and He, Jianlin and Wu, Zhipeng and He, Weigang and Dai, Xiaoming and Xu, Yan and Cheng, Min and Yang, Na and Ren, Yongxin and Wang, Guanglin and Wang, Jian and Sai, Yang and Jia, Hong and Dai, Guangxiu and Li, Xiong and Su, Weiguo},
  title = {Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor},
  journal = {The Journal of Pharmacology and Experimental Therapeutics},
  year = {2024},
  volume = {388},
  number = {1},
  pages = {156--170},
  doi = {10.1124/jpet.123.001752}
}
Kostenlos starten →